SCHAFFER DAVID 4
4 · 4D Molecular Therapeutics Inc. · Filed Sep 29, 2021
Insider Transaction Report
Form 4
SCHAFFER DAVID
Director10% Owner
Transactions
- Sale
Common Stock
2021-09-28$30.52/sh−13,812$421,493→ 966,856 total - Sale
Common Stock
2021-09-27$32.59/sh−13,075$426,076→ 986,925 total - Sale
Common Stock
2021-09-27$34.19/sh−100$3,419→ 980,668 total - Sale
Common Stock
2021-09-27$33.51/sh−6,157$206,330→ 980,768 total - Sale
Common Stock
2021-09-28$32.00/sh−100$3,200→ 966,756 total
Footnotes (5)
- [F1]Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
- [F2]The transaction was executed in multiple trades in prices ranging from $32.09 to $33.09, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F3]Since the date of the reporting person's last ownership report, he transferred 1,000,000 shares of FDMT common stock to his ex-spouse pursuant to a domestic relations order. The reporting person no longer reports as beneficially owned any securities owned by his ex-spouse.
- [F4]The transaction was executed in multiple trades in prices ranging from $33.10 to $34.01, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F5]The transaction was executed in multiple trades in prices ranging from $30.28 to $31.19, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.